Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07104396

Cogito: A Turnkey Solution for Rapidly Developing, Evaluating, Deploying, and Scaling Digital Therapeutics

This is a research study to evaluate the usability of the Cogito digital therapeutics development platform.

The Cogito platform is designed to allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with no programming skills necessary. It will provide the components for building a digital therapeutic for any health condition and population.

And in this initial study, the research team plans to examine the usability of Cogito in building a digital therapeutic for substance use disorders (SUDs).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Substance Use Disorders (SUDs) Chemically-Induced Disorders Mental Disorders Substance-Related Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Square 2 Systems

Hanover, New Hampshire, 03755, United States

Location status: Recruiting

Location contact

Research Coordinator

CONTACT

(802) 526-4608

About this study

Each participant will be asked to:

  • Complete an interactive tutorial describing what Cogito is and how to create a sample guide, sample activities, and a sample survey.
  • Explore using the various Cogito processes by completing a "functionality scavenger hunt". In this scavenger hunt, participants will be walked through a series of activities to create new guides, activities and surveys.
  • Complete surveys to provide feedback on participants' experience using Cogito

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years
  • PhD and/or MD-level (or equivalent) scientists at academic institutions or digital health companies at the level of Post-doctoral Fellow or higher.
  • Training or trained in substance use disorder (SUDs) research.
  • Must state a specific interest in digital therapeutics for SUDs.

Exclusion criteria

  • Those who do not meet inclusion criteria.

Treatment and study plan

Cogito digital therapeutics development platform

Other

Cogito will provide a turnkey solution for rapidly developing, evaluating, deploying, and scaling digital therapeutics for the prevention, treatment and/or management of any disease or disorder. This platform will allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with no programming skills necessary. It will provide all the components for building a digital therapeutic for any health condition and population. Overall, Cogito offers great promise to markedly accelerate the pace and impact of science based digital therapeutics.

Primary outcomes

  1. System Usability Scale

    Time frame: To be completed immediately after usability feedback session

    Each participant will be asked to complete the standardized 10-item System Usability Scale (SUS) to evaluate the usability of Cogito (e.g., "I think I would like to use this system frequently"), ranging from "strongly agree" to "strongly disagree".

Secondary outcomes

  1. Visual Analog Scales

    Time frame: To be completed immediately after usability feedback session

    100 mm Visual Analog measures, ranging from "Not at All" anchored at 0 to "Very" anchored at 100 for each question, with every question worded positively to assess how (1) easy to use, (2) understandable, (3) likable, (4) useful (5) relevant they found the Cogito development functionality in each stage of the scavenger hunt as well as (6) how likely they would be to use Cogito as a digital therapeutics development and hosting platform.

Study contacts

Contact information is provided by the study sponsor or research team.

Square2 Systems

CONTACT

(802) 526-4608

Sponsors and collaborators

Lead sponsor

Square2 Systems, Inc.

Industry

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 5, 2025
Registry last updated
Aug 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.